From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
Synonyms N,N-Didesmethyl-4,4'-dihydroxytamoxifen
Chemical and physical data
Formula C24H25NO3
Molar mass 375.47 g·mol−1
3D model (JSmol)

4'-Hydroxynorendoxifen is a synthetic, nonsteroidal antiestrogen of the triphenylethylene group.[1][2] It is a dual selective estrogen receptor modulator (SERM) and aromatase inhibitor (AI), and was derived from tamoxifen, a SERM, and norendoxifen, a metabolite of tamoxifen that has been found to act as an AI.[1][2] The drug has been suggested for potential development as a treatment for estrogen receptor (ER)-positive breast cancer.[1][2] It was synthesized in 2015.[1]


  1. ^ a b c d Lv W, Liu J, Skaar TC, Flockhart DA, Cushman M (2015). "Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities". J. Med. Chem. 58 (6): 2623–48. doi:10.1021/jm501218e. PMC 4687028Freely accessible. PMID 25751283. 
  2. ^ a b c Nagini, S. (2017). Breast cancer: current molecular therapeutic targets and new players. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 17(2), 152–163.